STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

Also called NCT03385928

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 201 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03385928
Other papers using this trial's data
  • Tranexamic acid versus placebo in individuals with intracerebral haemorrhage treated within 2 h of symptom onset (STOP-MSU): an international, double-blind, randomised, phase 2 trial The Lancet. Neurology, 2024-06 DOI, PubMed 38648814

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Finland, New Zealand, Taiwan, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03385928. Randomized; quadruple masking; primary purpose treatment. Start 2018-03-19 (actual); primary completion 2023-05-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units
Condition
Intracerebral Haemorrhage
Intervention (Drug)
Tranexamic Acid
Intervention (Drug)
Normal saline
Lead sponsor
Neuroscience Trials Australia (class: other)
Collaborator
The Florey Institute of Neuroscience and Mental Health (class: other)

Record details

Record id
cardio:ct-nct03385928
Content hash
1bd8a7124a13ddffc7b2d33f95475abdf03e625ca9e0149194fcd13ce3fd6c13